Visual Abstract

Background: Although diffuse alveolar damage and respiratory failure are the key features of coronavirus disease 2019 (COVID-19), the involvement of other organs such as the kidney has also been reported. The reports of the incidence of acute kidney injury (AKI) in COVID-19 patients vary widely. In this study, we report our unique experience with AKI in COVID-19 patients in a low socioeconomic and predominantly ethnic minority group and provide its incidence, risk factors, and prognosis to expand the current understanding of this complication. Methods: In this single-center, retrospective cohort study, we analyzed the data of 469 COVID-19 patients admitted to the Brookdale University Hospital in Brooklyn, NY, from March 18 through April 23, 2020. Information regarding demographics, comorbidities, medications, clinical and laboratory data, and outcomes was collected from the electronic medical records. Both univariate and multivariate analyses were performed to determine the association of AKI with in-hospital mortality. Results: The median age was 66 years (interquartile range [IQR] 25–75; range 19–101 years), and 268 (57.14%) patients were male. Estimated glomerular filtration rate (eGFR) as determined by the Modification of Diet in Renal Disease Study Equation was low (<60 mL/min/1.73 m2) in 207 (44.1%) patients. During hospitalization, 128 (27.3%) patients developed AKI, and the incidence was significantly higher in those patients presenting with a low eGFR (N = 81, 39.1%; p < 0.001). Male sex, hypertension, the use of angiotensin-converting enzyme inhibitors and non-steroidal anti-inflammatories, hemodynamic instability, mechanical ventilation, acute respiratory distress syndrome, and admission elevated ferritin, creatinine kinase, brain natriuretic peptide, and troponin 1 were identified as the risk factors for in-hospital AKI. Ninety-seven (28.45%) patients died in the non-AKI group versus 91 (71.1%) in the AKI group (p < 0.001). The Cox proportional hazard model after adjusting for age, gender, comorbidities, hemodynamic status, and PF ratio (arterial oxygen partial pressure [PaO2]/fractional inspired oxygen [FiO2]) determined that on admission, an elevated blood urea nitrogen (hazard ratio [HR]: 1.75; 95% confidence interval [CI] 1.23–2.48), a low eGFR (HR 1.43; CI 1.1–2.03), AKI stage 1 (HR 1.14; CI 0.64–2.03), AKI stage 2 (HR 1.86; CI 1.03–3.56), and AKI stage 3 (HR 2.1; CI 1.3–2.81) were independent risk factors for in-hospital mortality. Renal replacement therapy (RRT) did not improve survival in stage III AKI. Conclusion: AKI in our hospitalized COVID-19 patients was common and carried a high mortality, especially in patients with AKI stage 3. RRT did not improve survival. Policy changes and planning for this high incidence of AKI in COVID-19 patients and its associated high mortality are necessary at the local and national levels.

1.
Huang
C
,
Wang
Y
,
Li
X
,
Ren
L
,
Zhao
J
,
Hu
Y
, et al.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
.
Lancet
.
2020
;
395
(
10223
):
497
506
. .
2.
Thebault
R
,
Ba Tran
A
,
Williams
V
.
The coronavirus is infecting and killing black Americans at an alarmingly high rate
. Washington Post. 2020 Apr 7. Available from: https://www.washingtonpost.com/nation/2020/04/07/coronavirus-is-infecting-killing-black-americans-an-alarmingly-high-rate-post-analysis-shows/.
3.
Yancy
CW
.
COVID-19 and African Americans
.
JAMA
.
2020
;
323
(
19
):
1891
2
. .
4.
Hirsch
JS
,
Ng
JH
,
Ross
DW
,
Sharma
P
,
Shah
HH
,
Barnett
RL
, et al.
Acute kidney injury in patients hospitalized with COVID-19
.
kidney Int
.
2020 Jul
;
98
(
1
):
209
18
.
Epub 2020 May 16
. .
5.
Cheng
Y
,
Luo
R
,
Wang
K
,
Zhang
M
,
Wang
Z
,
Dong
L
, et al.
Kidney disease is associated with in-hospital death of patients with COVID-19
.
Kidney Int
.
2020
;
97
(
5
):
829
38
.
ISSN 0085–2538
. .
6.
Wang
L
,
Li
X
,
Chen
H
,
Yan
S
,
Li
D
,
Li
Y
.
Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China
.
Am J Nephrol
.
2020
;
51
(
5
):
343
8
.
7.
Wang
D
,
Hu
B
,
Hu
C
,
Zhu
F
,
Liu
X
,
Zhang
J
, et al.
Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China
.
JAMA
.
2020
;
323
(
11
):
1061
. .
8.
Hong
KS
,
Lee
KH
,
Chung
JH
,
Shin
KC
,
Choi
EY
,
Jin
HJ
, et al.
Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study
.
Yonsei Med J
.
2020 May
;
61
(
5
):
431
7
. .
9.
Fanelli
V
,
Fiorentino
M
,
Cantaluppi
V
,
Gesualdo
L
,
Stallone
G
,
Ronco
C
, et al.
Acute kidney injury in SARS-CoV-2 infected patients
.
Crit Care
.
2020
;
24
(
1
):
155
.
Published 2020 Apr 16
. .
10.
Hoffmann
M
,
Kleine‐Weber
H
,
Krüger
N
,
Müller
M
,
Drosten
C
,
Pöhlmann
S
.
The novel coronavirus 2019 (2019‐nCoV) uses the SARS‐coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
.
bioRxiv
.
2020
. Posted 2020 Jan 31.
11.
Zhao
Y
,
Zhao
Z
,
Wang
Y
,
Zhou
Y
,
Ma
Y
,
Zuo
W
.
Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov
.
bioRxiv
.
2020
.
12.
Hamming
I
,
Timens
W
,
Bulthuis
ML
,
Lely
AT
,
Navis
G
,
van Goor
H
.
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
.
J Pathol
.
2004
;
203
(
2
):
631
. .
13.
Su
H
,
Yang
M
,
Wan
C
,
Yi
LX
,
Tang
F
,
Zhu
HY
.
Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China
.
Kidney Int
.
2020 Jul
;
98
(
1
):
219
27
.
Epub 2020 Apr 9
. .
14.
Khwaja
A
.
KDIGO clinical practice guidelines for acute kidney injury
.
Nephron Clin Pract
.
2012
;
120
(
4
):
c179
84
. .
15.
Khadzhynov
D
,
Schmidt
D
,
Hardt
J
,
Rauch
G
,
Gocke
P
,
Eckardt
KU
, et al.
The incidence of acute kidney injury and associated hospital mortality
.
Dtsch Arztebl Int
.
2019
;
116
(
22
):
397
404
. .
16.
Sawhney
S
,
Marks
A
,
Fluck
N
,
Levin
A
,
Prescott
G
,
Black
C
.
Intermediate and long-term outcomes of survivors of acute kidney injury episodes: a large population-based cohort study
.
Am J Kidney Dis
.
2017
;
69
(
1
):
18
28
. .
17.
Wang
HE
,
Muntner
P
,
Chertow
GM
,
Warnock
DG
.
Acute kidney injury and mortality in hospitalized patients
.
Am J Nephrol
.
2012
;
35
(
4
):
349
55
. .
18.
Batlle
D
,
Soler
MJ
,
Sparks
MA
,
Hiremath
S
,
South
AM
,
Welling
P
, et al.
Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology
.
J Am Soc Nephrol
.
2020 Jul
;
31
(
7
):
1380
3
.
19.
Ferrario
CM
,
Jessup
J
,
Chappell
MC
,
Averill
DB
,
Brosnihan
KB
,
Tallant
EA
, et al.
Effect of angiotensin‐converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin‐converting enzyme 2
.
Circulation
.
2005
;
111
(
20
):
2605
10
. .
20.
Vuille‐dit‐Bille
RN
,
Camargo
SM
,
Emmenegger
L
,
Sasse
T
,
Kummer
E
,
Jando
J
, et al.
Human intestine luminal ACE2 and amino acid transporter expression increased by ACE‐inhibitors
.
Amino Acids
.
2015
;
47
:
693
705
.
21.
Kuba
K
,
Imai
Y
,
Rao
S
,
Gao
H
,
Guo
F
,
Guan
B
, et al.
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus‐induced lung injury
.
Nat Med
.
2005
;
11
:
875
9
.
22.
Gu
H
,
Xie
Z
,
Li
T
,
Zhang
S
,
Lai
C
,
Zhu
P
, et al.
Angiotensin‐converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus
.
Sci Rep
.
2016
;
6
:
19840
. .
23.
Wadhera
RK
,
Wadhera
P
,
Gaba
P
,
Figueroa
JF
,
Joynt Maddox
KE
,
Yeh
RW
, et al.
Variation in COVID-19 hospitalizations and deaths across New York city boroughs
.
JAMA
.
2020
;
323
(
21
):
2192
5
. .
24.
NYC Health. COVID-19: data. Accessed 2020 May 7. Available from: https://www1.nyc.gov/site/doh/covid/covid-19-data.page
.
25.
King
L
,
Hinterland
K
,
Dragan
KL
,
Driver
CR
,
Harris
TG
,
Gwynn
RC
, et al.
Community health profiles 2015
. Brooklyn Community District 16: Brownsville.
2015
;
40
(
59
):
1
16
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.